Kyowa Kirin signs Poteligeo deal as 11 analysts rate Kyowa Kirin stock Underperform

Knight will distribute mogamulizumab in four Latin American markets. Kyowa Kirin stock stands between JPY 2,109.00 and JPY 2,912.00 as of October 2, 2026.

Kyowa Kirin International signed an exclusive Poteligeo distribution agreement for Latin America on September 29, 2026, while 11 analysts carried an Underperform consensus for Kyowa Kirin stock. The agreement gives Knight Therapeutics exclusive rights in Brazil, Mexico, Colombia and Argentina, according to GlobeNewswire.

Poteligeo enters four markets

Knight will handle regulatory submissions and commercialization of mogamulizumab, sold as Poteligeo, in Brazil, Mexico, Colombia and Argentina. The medicine is approved in the United States and Europe for adults with relapsed or refractory mycosis fungoides or Sezary syndrome after at least one prior systemic therapy, the GlobeNewswire release said.

The commercial logic is clear: Kyowa Kirin adds a new geographic route for an existing oncology product, while Knight takes on local approval and launch work. The agreement is therefore an expansion of access rather than a newly announced drug discovery program.

Tokyo shares remain under pressure

Kyowa Kirin traded at JPY 2,248.50 on the Tokyo Stock Exchange on October 2, 2026 at 9:50 a.m. JST, down 1.62 percent from the JPY 2,285.50 prior close. Its market capitalization was JPY 1.2 trillion, while the 52-week range stood between JPY 2,109.00 and JPY 2,912.00 on the same date.

Simply Wall St reported on October 1, 2026, that Kyowa Kirin's 30-day share-price return was minus 14.61 percent and its 90-day return was minus 13.85 percent. That performance puts the Latin American agreement against a clear recent price-pressure backdrop.

Analyst caution meets new access

MarketScreener listed an Underperform consensus from 11 analysts, an average target of JPY 2,281.82 and a last close of JPY 2,262.50. The average target was JPY 19.32 above that listed close, a gap of 0.85 percent.

Jefferies separately downgraded Kyowa Kirin to Hold from Buy and cut its target from JPY 2,800.00 to JPY 2,600.00, according to MarketScreener. The contrast is material for investors: regional expansion is advancing, but the published analyst view remains cautious.

Prior close remains EUR 20.85

The Lang & Schwarz prior close was EUR 20.85 on September 30, 2026. Kyowa Kirin Co., Ltd. is listed on the Tokyo Stock Exchange under ticker 4151, and its market value was JPY 1.2 trillion as of October 2, 2026.

Kyowa Kirin stock facts

• Company: Kyowa Kirin Co., Ltd.
• Ticker: 4151
• Primary exchange: Tokyo Stock Exchange
• Prior close Lang & Schwarz (September 30, 2026): EUR 20.85
• Market capitalization: JPY 1.2 trillion (as of October 2, 2026)
• 52-week range: JPY 2,109.00-2,912.00 (as of October 2, 2026)
• Sector / Industry: Healthcare / Medical Pharmaceuticals